Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer.

Kulshrestha RK, Vinjamuri S, England A, Nightingale J, Hogg P.

J Nucl Med Technol. 2016 Dec;44(4):217-222. Epub 2016 Sep 15. Review.

2.

Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.

Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A.

J Nucl Med. 2015 Dec;56(12):1862-8. doi: 10.2967/jnumed.115.162610. Epub 2015 Sep 24.

3.

18F-NaF-PET/CT and 99mTc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer.

Langsteger W, Rezaee A, Pirich C, Beheshti M.

Semin Nucl Med. 2016 Nov;46(6):491-501. doi: 10.1053/j.semnuclmed.2016.07.003. Epub 2016 Sep 13. Review.

PMID:
27825429
4.

99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer.

Wondergem M, van der Zant FM, Knol RJJ, Burgers AMG, Bos SD, de Jong IJ, Pruim J.

World J Urol. 2018 Jan;36(1):27-34. doi: 10.1007/s00345-017-2096-3. Epub 2017 Oct 17.

5.

Technical feasibility, radiation dosimetry and clinical use of 18F-sodium fluoride (NaF) in evaluation of metastatic bone disease in pediatric population.

Usmani S, Van den Wyngaert T, Ahmed N, Marafi F, Esmail A, Al Kandari F, Al Nuaimi M, Gnanasegaran G.

Ann Nucl Med. 2018 Nov;32(9):594-601. doi: 10.1007/s12149-018-1279-3. Epub 2018 Jul 17.

PMID:
30019285
6.

A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases.

Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, Oturai P, Jensen KE, Mørk ML, Reichkendler M, Højgaard L, Fischer BM.

J Nucl Med. 2017 Nov;58(11):1778-1785. doi: 10.2967/jnumed.116.189183. Epub 2017 Aug 10.

7.

Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.

Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1873-1883. doi: 10.1007/s00259-018-4048-6. Epub 2018 May 16.

PMID:
29766246
8.

Prospective comparative study of 18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer.

Fonager RF, Zacho HD, Langkilde NC, Fledelius J, Ejlersen JA, Hendel HW, Haarmark C, Moe M, Mortensen JC, Jochumsen MR, Petersen LJ.

Acta Oncol. 2018 Aug;57(8):1063-1069. doi: 10.1080/0284186X.2018.1438651. Epub 2018 Feb 15.

PMID:
29447047
9.

Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient management in patients with breast carcinoma.

Broos WAM, van der Zant FM, Wondergem M, Knol RJJ.

Nucl Med Commun. 2018 Apr;39(4):325-333. doi: 10.1097/MNM.0000000000000807.

PMID:
29351123
10.

Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.

Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H, Saunavaara J, Noponen T, Minn H, Aronen HJ, Seppänen M.

Acta Oncol. 2016;55(1):59-67. doi: 10.3109/0284186X.2015.1027411. Epub 2015 Apr 2.

PMID:
25833330
11.

Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice.

Bastawrous S, Bhargava P, Behnia F, Djang DS, Haseley DR.

Radiographics. 2014 Sep-Oct;34(5):1295-316. doi: 10.1148/rg.345130061. Review.

PMID:
25208282
12.

The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.

Yen RF, Chen CY, Cheng MF, Wu YW, Shiau YC, Wu K, Hong RL, Yu CJ, Wang KL, Yang RS.

Nucl Med Commun. 2010 Jul;31(7):637-45. doi: 10.1097/MNM.0b013e3283399120.

PMID:
20389259
13.

Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer.

Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, Dettmann K, Langkilde NC, Haarmark C, Fisker RV, Arp DT, Carl J, Jensen JB, Petersen LJ.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1884-1897. doi: 10.1007/s00259-018-4058-4. Epub 2018 Jun 6.

PMID:
29876619
14.

Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.

Beheshti M, Rezaee A, Geinitz H, Loidl W, Pirich C, Langsteger W.

J Nucl Med. 2016 Oct;57(Suppl 3):55S-60S. Review.

15.

Diagnostic Challenge of Staging Metastatic Bone Disease in the Morbidly Obese Patients: A Primary Study Evaluating the Usefulness of 18F-Sodium Fluoride (NaF) PET-CT.

Usmani S, Marafi F, Ahmed N, Esmail A, Al Kandari F, Van den Wyngaert T.

Clin Nucl Med. 2017 Nov;42(11):829-836. doi: 10.1097/RLU.0000000000001823.

PMID:
28872551
16.

Evaluation of bone-seeking novel radiotracer 68Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breast.

Passah A, Tripathi M, Ballal S, Yadav MP, Kumar R, Roesch F, Meckel M, Sarathi Chakraborty P, Bal C.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):41-49. Epub 2016 Jul 25.

PMID:
27455986
17.

Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.

Roop MJ, Singh B, Singh H, Watts A, Kohli PS, Mittal BR, Singh G.

Clin Nucl Med. 2017 May;42(5):335-340. doi: 10.1097/RLU.0000000000001615.

PMID:
28263210
18.

Atlas of Extraosseous Findings Detected by 18F-NaF PET/CT Bone Scan.

Woodhead GJ, Avery RJ, Kuo PH.

Clin Nucl Med. 2017 Dec;42(12):930-938. doi: 10.1097/RLU.0000000000001861.

PMID:
29036001
19.

Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.

Iagaru A, Young P, Mittra E, Dick DW, Herfkens R, Gambhir SS.

Clin Nucl Med. 2013 Jul;38(7):e290-6. doi: 10.1097/RLU.0b013e3182815f64.

PMID:
23455520
20.

Skeletal PET with 18F-fluoride: applying new technology to an old tracer.

Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST.

J Nucl Med. 2008 Jan;49(1):68-78. Epub 2007 Dec 12. Review.

Supplemental Content

Support Center